Title: OX40:OX40L Axis: Emerging Targets for Immunotherapy of Human Disease
Volume: 2
Issue: 1
Author(s): Shahram Salek-Ardakani, Aihua Song, Ian R. Humphreys and Michael Croft
Affiliation:
Keywords:
T cells, OX40, OX40L, immunotherapy, autoimmunity, transplantation, allergy, viruses, cancer
Abstract: Recent advances in our understanding of the mechanisms through which T cells are activated have led to new therapeutic approaches in the treatment of immunological disorders. An emerging target for selective immune intervention has been the manipulation of T cell costimulatory pathways. Impressive results in animal models have shown that the tumor-necrosis-factor receptor (TNFR) family member, OX40 (CD134), and its binding partner OX40L, are key costimulatory molecules involved in the regulation of many T cell mediated immune disorders. In this review we will highlight these new findings with a particular emphasis on their potential implications for immunotherapy of human disease.
